Cargando…

Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis

RATIONALE: Forced expiratory volume in 1 s (FEV1) decline (ΔFEV1) is associated with pulmonary exacerbation (PEx) diagnosis in cystic fibrosis (CF). Spirometry may not be available during telehealth visits and could impair clinician ability to diagnose PEx. This study aims to (1) identify the associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouzek, Drake C., Ren, Clement L., Thompson, Misty, Slaven, James E., Sanders, Don B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321873/ https://www.ncbi.nlm.nih.gov/pubmed/35429154 http://dx.doi.org/10.1002/ppul.25925

Ejemplares similares

Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV(1) decline
por: de Aquino, Carolina Silva Barboza, et al.
Publicado: (2022)

Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis
por: Cousin, Mathias, et al.
Publicado: (2016)

Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis
por: Boëlle, Pierre-Yves, et al.
Publicado: (2012)

Understanding the natural progression in %FEV(1) decline in patients with cystic fibrosis: a longitudinal study
por: Taylor-Robinson, David, et al.
Publicado: (2012)

Variability of FEV(1) and Criterion for Acute Pulmonary Exacerbation
por: Jenkins, Bradlee A., et al.
Publicado: (2014)

Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation
por: Hassanzad, Maryam, et al.
Publicado: (2021)

Decline in FEV(1) and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency
por: Hiller, Adriana-Maria, et al.
Publicado: (2019)

Glucose Tolerance during Pulmonary Exacerbations in Children with Cystic Fibrosis
por: Widger, John, et al.
Publicado: (2012)

Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis
por: Asner, Sandra, et al.
Publicado: (2012)

Antibiotic duration and changes in FEV(1) are not associated with time until next exacerbation in adult cystic fibrosis: a single center study
por: Espel, Julia C., et al.
Publicado: (2017)

Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations
por: Merjaneh, Lina, et al.
Publicado: (2020)

Clinical impact of respiratory virus in pulmonary exacerbations of children with Cystic Fibrosis
por: Meyer, Viviane Mauro Correa, et al.
Publicado: (2020)

Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation
por: Walicka-Serzysko, Katarzyna, et al.
Publicado: (2021)

Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
por: Sawant, Akhil, et al.
Publicado: (2018)

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
por: Wojsyk-Banaszak, I., et al.
Publicado: (2019)

Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis()
por: Hoppe, Jordana E., et al.
Publicado: (2018)

BMI is associated with FEV(1) decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials
por: Sun, Yilan, et al.
Publicado: (2019)

1315. Ceftaroline Versus Vancomycin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis in Adults
por: Esquivel, Marc, et al.
Publicado: (2021)

Rate of Decline of FEV(1) as a Biomarker of Survival?
por: Papi, Alberto, et al.
Publicado: (2021)

Plasma sCD14 as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis
por: Quon, Bradley S., et al.
Publicado: (2014)

Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis
por: Li, Dan, et al.
Publicado: (2017)

Multivariate joint modeling to identify markers of growth and lung function decline that predict cystic fibrosis pulmonary exacerbation onset
por: Andrinopoulou, E. R., et al.
Publicado: (2020)

Association between hypovitaminosis D and frequency of pulmonary exacerbations in children and adolescents with cystic fibrosis
por: Ongaratto, Renata, et al.
Publicado: (2018)

Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
por: DiMango, Emily, et al.
Publicado: (2014)

Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
por: Zemanick, Edith T., et al.
Publicado: (2013)

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations
por: Skolnik, Kate, et al.
Publicado: (2018)

Rhinovirus C and Respiratory Exacerbations in Children with Cystic Fibrosis
por: de Almeida, Marina B., et al.
Publicado: (2010)

Median regression spline modeling of longitudinal FEV(1) measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients
por: Conrad, Douglas J., et al.
Publicado: (2017)

EPS4.4 Correlation between long-term changes in LCI, FEV(1) and CFCT score in children with cystic fibrosis
por: Vermeulen, F., et al.
Publicado: (2017)

BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis
por: Schultz, Andre, et al.
Publicado: (2023)

Inhaled corticosteroids and FEV(1) decline in chronic obstructive pulmonary disease: a systematic review
por: Whittaker, Hannah R., et al.
Publicado: (2019)

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study
por: Wells, J. Michael, et al.
Publicado: (2016)

Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape
por: Stanford, Gemma E., et al.
Publicado: (2021)

Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2017)

Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations
por: Tabatabaii, Seyed Ahmad, et al.
Publicado: (2020)

Measuring the impact of an empiric antibiotic algorithm for pulmonary exacerbation in children and young adults with cystic fibrosis
por: Kennedy, Charles, et al.
Publicado: (2022)

Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease
por: Quinn, Robert A., et al.
Publicado: (2016)

The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis
por: Al-Aloul, Mohamed, et al.
Publicado: (2019)

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?
por: Thornton, Christina, et al.
Publicado: (2021)

Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations
por: Waters, Valerie
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qddlb63lbfqrcg6ri4olbhn7cs